Hallucinogens potentiate responses to serotonin and norepinephrine in the facial motor nucleus.
D000818:Animals; D004357:Drug Synergism; D005154:Facial Nerve / Q000187:drug effects*; D006213:Hallucinogens / Q000494:pharmacology*; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D008238:Lysergic Acid Diethylamide / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D008635:Mescaline / Q000494:pharmacology; D009046:Motor Neurons / Q000187:drug effects*; D009638:Norepinephrine / Q000494:pharmacology*; D011562:Psilocybin / Q000494:pharmacology; D051381:Rats; D012701:Serotonin / Q000494:pharmacology*
D006213:Hallucinogens; D011562:Psilocybin; D012701:Serotonin; D008238:Lysergic Acid Diethylamide; D008635:Mescaline; D009638:Norepinephrine